MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9
暂无分享,去创建一个
C. Cordon-Cardo | Jose M. Silva | M. Castillo-Martin | A. Jia | D. Bonal | M. Sánchez-Carbayo | J. M. Silva
[1] C. Cordon-Cardo,et al. A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. , 2013, The American journal of pathology.
[2] Hua-mei Tang,et al. Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma , 2013, Clinical & Experimental Metastasis.
[3] Y. Akao,et al. Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. , 2013, Cancer letters.
[4] Paul Hofman,et al. Two Panels of Plasma MicroRNAs as Non-Invasive Biomarkers for Prediction of Recurrence in Resectable NSCLC , 2013, PloS one.
[5] R. Dahiya,et al. Oncogenic miRNA-182-5p Targets Smad4 and RECK in Human Bladder Cancer , 2012, PloS one.
[6] R. Dahiya,et al. MicroRNA-1280 Inhibits Invasion and Metastasis by Targeting ROCK1 in Bladder Cancer , 2012, PloS one.
[7] U. Bhawal,et al. Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer , 2012, British Journal of Cancer.
[8] N. Seki,et al. Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. , 2012, Urologic oncology.
[9] N. Seki,et al. Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. , 2012, International journal of oncology.
[10] N. Seki,et al. Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. , 2012, Biochemical and biophysical research communications.
[11] Martin Krapcho,et al. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .
[12] W. Fujibuchi,et al. MiR-126 Acts as a Tumor Suppressor in Pancreatic Cancer Cells via the Regulation of ADAM9 , 2011, Molecular Cancer Research.
[13] N. Seki,et al. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer , 2011, British Journal of Cancer.
[14] Michael W. Pfaffl,et al. Normalization Strategies for Microrna Profiling Experiments: a 'normal' Way to a Hidden Layer of Complexity? , 2010 .
[15] M. Knowles,et al. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. , 2010, Urologic oncology.
[16] N. Seki,et al. 821 MIR-145 AND MIR-133A FUNCTION AS TUMOUR SUPPRESSORS AND DIRECTLY REGULATE FSCN1 EXPRESSION IN BLADDER CANCER , 2010 .
[17] N. Seki,et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer , 2010, British Journal of Cancer.
[18] M. Duffy,et al. Role of ADAMs in Cancer Formation and Progression , 2009, Clinical Cancer Research.
[19] W. Gerald,et al. Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.
[20] C. Cordon-Cardo. Molecular alterations associated with bladder cancer initiation and progression , 2008, Scandinavian journal of urology and nephrology. Supplementum.
[21] Wayne Tam,et al. MicroRNAs in tumorigenesis: a primer. , 2007, The American journal of pathology.
[22] F. Marshall,et al. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. , 2006, Cancer research.
[23] Michael W Pfaffl,et al. RNA integrity and the effect on the real-time qRT-PCR performance. , 2006, Molecular aspects of medicine.
[24] F. Slack,et al. Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.
[25] C. Blobel,et al. Critical function for ADAM9 in mouse prostate cancer. , 2005, Cancer research.
[26] M. Knowles,et al. Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype , 2005, Clinical Cancer Research.
[27] T. Libermann,et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. , 2005, Cancer research.
[28] C. Blobel,et al. ADAMs: key components in EGFR signalling and development , 2005, Nature Reviews Molecular Cell Biology.
[29] Lin He,et al. MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.
[30] S. Yamamoto,et al. Overexpression of ADAM9 in Non-Small Cell Lung Cancer Correlates with Brain Metastasis , 2004, Cancer Research.
[31] T. Du,et al. Asymmetry in the Assembly of the RNAi Enzyme Complex , 2003, Cell.
[32] M. Duffy,et al. Expression of ADAM‐9 mRNA and protein in human breast cancer , 2003, International journal of cancer.
[33] G. Baffet,et al. ADAM12 in human liver cancers: TGF‐β‐regulated expression in stellate cells is associated with matrix remodeling , 2003, Hepatology.
[34] L. Moore,et al. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest , 2000, Oncogene.
[35] François G. Meyer,et al. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. , 1999, The American journal of pathology.
[36] J. Herman,et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers , 1998, Oncogene.
[37] C. Cordon-Cardo,et al. Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. , 1996, The American journal of pathology.
[38] M. Knowles,et al. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. , 1991, Oncogene.
[39] C. Cordon-Cardo,et al. Molecular genetic alterations in superficial and locally advanced human bladder cancer. , 1991, Cancer research.